Literature DB >> 9347598

Gabapentin for the treatment of spasticity in patients with spinal cord injury.

M Gruenthal1, M Mueller, W L Olson, M M Priebe, A M Sherwood, W H Olson.   

Abstract

Our serendipitous observations suggested that some patients with spasticity appeared to have improved following the administration of the anticonvulsant drug gabapentin. As some patients with spasticity are either refractory to or intolerant of established medical treatments, we conducted this study to investigate the effect of gabapentin on spasticity in patients with spinal cord injury. Twenty-five patients with spinal cord injury and spasticity received oral gabapentin (2400 mg over 48 h) in a randomized, double blind, placebo-controlled crossover study. We assessed responses by measuring the Ashworth spasticity scale, muscle stretch reflexes, presence of clonus and reflex response to noxious stimuli. Patient ratings were obtained using a Likert Scale. Administration of gabapentin, but not placebo, was associated with an 11% reduction in spasticity as measured by the Ashworth Scale (P = 0.04) and by a 20% reduction in the Likert Scale (P = 0.0013). Significant changes were not obtained for the other measures. The data obtained suggest that gabapentin may be useful in the management of spasticity associated with spinal cord injury.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9347598     DOI: 10.1038/sj.sc.3100481

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  12 in total

Review 1.  Neuropathic Pain After Spinal Cord Injury: Challenges and Research Perspectives.

Authors:  Rani Shiao; Corinne A Lee-Kubli
Journal:  Neurotherapeutics       Date:  2018-07       Impact factor: 7.620

Review 2.  Latest approaches for the treatment of spasticity and autonomic dysreflexia in chronic spinal cord injury.

Authors:  Alexander G Rabchevsky; Patrick H Kitzman
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

3.  A Review of Spasticity Treatments: Pharmacological and Interventional Approaches.

Authors:  Eric Chang; Nilasha Ghosh; Daniel Yanni; Sujin Lee; Daniela Alexandru; Tahseen Mozaffar
Journal:  Crit Rev Phys Rehabil Med       Date:  2013

Review 4.  WITHDRAWN: Gabapentin for acute and chronic pain.

Authors:  Philip J Wiffen; Henry J McQuay; Jayne Edwards; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

Review 5.  Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis.

Authors:  R T Schapiro
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

Review 6.  Efficacy of pregabalin and gabapentin for neuropathic pain in spinal-cord injury: an evidence-based evaluation of the literature.

Authors:  Thrasivoulos G Tzellos; Georgios Papazisis; Ekaterini Amaniti; Dimitrios Kouvelas
Journal:  Eur J Clin Pharmacol       Date:  2008-07-08       Impact factor: 2.953

Review 7.  Rehabilitation medicine: 3. Management of adult spasticity.

Authors:  Lalith E Satkunam
Journal:  CMAJ       Date:  2003-11-25       Impact factor: 8.262

Review 8.  The pharmacological management of post-stroke muscle spasticity.

Authors:  Abdel Magid O Bakheit
Journal:  Drugs Aging       Date:  2012-12       Impact factor: 3.923

9.  Flumazenil therapy for a gabapentin-induced coma: a case report.

Authors:  M Masciullo; F Pichiorri; G Scivoletto; C Foti; M Molinari
Journal:  J Med Case Rep       Date:  2021-05-09

10.  Effects of gabapentin on muscle spasticity and both induced as well as spontaneous autonomic dysreflexia after complete spinal cord injury.

Authors:  Alexander G Rabchevsky; Samir P Patel; Travis S Lyttle; Khalid C Eldahan; Christopher R O'Dell; Yi Zhang; Phillip G Popovich; Patrick H Kitzman; Kevin D Donohue
Journal:  Front Physiol       Date:  2012-08-15       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.